NCT04499963View on ClinicalTrials.gov

Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

August 30, 2022

Study Completion Date

August 30, 2022

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Theracurmin HP

The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment

Trial Locations (1)

27705

Duke University Medical Center, Durham

All Listed Sponsors
lead

Richard Bedlack, M.D., Ph.D.

OTHER

NCT04499963 - Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter